Fiche société
TG Therapeutics, Inc.
Traitements, essais et publications liés.
Traitements18programmes
Essais13liés
Publications2liées
SourceDBlocale
Traitements
18| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| Azercabtagene zapreleucel (azer-cel)The main objective of the study is to determine the recommended phase 2 dose (RP2D) of Azercabtagene zapreleucel (azer-cel). | Myasthénie | Phase 1 | À vérifier | United States | À vérifier |
| ENABLE — A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)The purpose of this study is to evaluate safety, effiectiveness, and to gain insight into the treatment experience of participants prescribed BRIUMVI® (ublituximab-xiiy) in the real-world setting | SEP | À vérifier | À vérifier | United States, Puerto Rico | À vérifier |
| Prefilled penThe purpose of this study is to evaluate the PK and safety of ublituximab SC at different sites of administration and relative bioavailability of ublituximab SC administered with a prefilled pen versus syringe. | SEP | Phase 2 | À vérifier | Bosnia and Herzegovina, Georgia, North Macedonia, Poland, Serbia, Ukraine | À vérifier |
| PROVIDE — A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast MilkThe primary objective of the lactation study is to characterize the presence and concentration of BRIUMVI™ in breast milk among breastfeeding participants who receive BRIUMVI™ therapeutically for the treatment of relapsing forms of multiple sclerosis (RMS). | SEP | À vérifier | À vérifier | United States | À vérifier |
| UblituximabThe proposed study is a pilot study of ublituximab involving people with multiple sclerosis (MS) who are experiencing a "wearing off" phenomenon (return or worsening of MS-related symptoms) while being treated with ocrelizumab, and exploring whether switching to ublituzimab can resolve, improve or delay this phenomenon. | Myasthénie, Myopathies, SEP | Phase 2 | Traitement symptomatique | United States | À vérifier |
| UmbralisibPhase I/II Study of Venetoclax or Lenalidomide in Combination with Ublituximab and Umbralisib in Subjects with Relapsed or Refractory CLL/SLL and NHL | SEP | Phase 1/2 | À vérifier | United States | À vérifier |
| UblituximabThe proposed study is a pilot study of ublituximab involving people with multiple sclerosis (MS) who are experiencing a "wearing off" phenomenon (return or worsening of MS-related symptoms) while being treated with ocrelizumab, and exploring whether switching to ublituzimab can resolve, improve or delay this phenomenon. | SEP | Phase 4 | Traitement symptomatique | United States | À vérifier |
| UblituximabThe proposed study is a pilot study of ublituximab involving people with multiple sclerosis (MS) who are experiencing a "wearing off" phenomenon (return or worsening of MS-related symptoms) while being treated with ocrelizumab, and exploring whether switching to ublituzimab can resolve, improve or delay this phenomenon. | Myopathies | Phase 2 | Traitement symptomatique | United States | À vérifier |
| Azercabtagene zapreleucel (azer-cel)The main objective of the study is to determine the recommended phase 2 dose (RP2D) of Azercabtagene zapreleucel (azer-cel). | Myasthénie | Phase 1 | United States | À vérifier | |
| UblituximabThe proposed study is a pilot study of ublituximab involving people with multiple sclerosis (MS) who are experiencing a "wearing off" phenomenon (return or worsening of MS-related symptoms) while being treated with ocrelizumab, and exploring whether switching to ublituzimab can resolve, improve or delay this phenomenon. | Myasthénie | Phase 2 | Traitement symptomatique | United States | À vérifier |
| UblituximabThe proposed study is a pilot study of ublituximab involving people with multiple sclerosis (MS) who are experiencing a "wearing off" phenomenon (return or worsening of MS-related symptoms) while being treated with ocrelizumab, and exploring whether switching to ublituzimab can resolve, improve or delay this phenomenon. | SEP | Non applicable | Traitement symptomatique | United States | À vérifier |
| UblituximabThe proposed study is a pilot study of ublituximab involving people with multiple sclerosis (MS) who are experiencing a "wearing off" phenomenon (return or worsening of MS-related symptoms) while being treated with ocrelizumab, and exploring whether switching to ublituzimab can resolve, improve or delay this phenomenon. | SEP | Phase 3 | Traitement symptomatique | Bosnia and Herzegovina, Bulgaria, Croatia, Czechia, Georgia, Hungary, North Macedonia, Serbia, Ukraine | À vérifier |
| PROVIDE — A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast MilkThe primary objective of the lactation study is to characterize the presence and concentration of BRIUMVI™ in breast milk among breastfeeding participants who receive BRIUMVI™ therapeutically for the treatment of relapsing forms of multiple sclerosis (RMS). | SEP | À vérifier | À vérifier | United States | À vérifier |
| UblituximabThe proposed study is a pilot study of ublituximab involving people with multiple sclerosis (MS) who are experiencing a "wearing off" phenomenon (return or worsening of MS-related symptoms) while being treated with ocrelizumab, and exploring whether switching to ublituzimab can resolve, improve or delay this phenomenon. | SEP | Phase 3 | Traitement symptomatique | United States, Belarus, Croatia, Georgia, Poland, Russia, Serbia, Ukraine | À vérifier |
| UblituximabThe proposed study is a pilot study of ublituximab involving people with multiple sclerosis (MS) who are experiencing a "wearing off" phenomenon (return or worsening of MS-related symptoms) while being treated with ocrelizumab, and exploring whether switching to ublituzimab can resolve, improve or delay this phenomenon. | SEP | Phase 3 | Traitement symptomatique | United States, Poland | À vérifier |
| ENABLE — A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)The purpose of this study is to evaluate safety, effiectiveness, and to gain insight into the treatment experience of participants prescribed BRIUMVI® (ublituximab-xiiy) in the real-world setting | SEP | À vérifier | À vérifier | United States, Puerto Rico | À vérifier |
| UblituximabThe proposed study is a pilot study of ublituximab involving people with multiple sclerosis (MS) who are experiencing a "wearing off" phenomenon (return or worsening of MS-related symptoms) while being treated with ocrelizumab, and exploring whether switching to ublituzimab can resolve, improve or delay this phenomenon. | SEP | Phase 2/3 | Traitement symptomatique | United States, Poland, Slovakia | À vérifier |
| UblituximabThe proposed study is a pilot study of ublituximab involving people with multiple sclerosis (MS) who are experiencing a "wearing off" phenomenon (return or worsening of MS-related symptoms) while being treated with ocrelizumab, and exploring whether switching to ublituzimab can resolve, improve or delay this phenomenon. | SEP | Phase 2 | Traitement symptomatique | Bosnia and Herzegovina, Georgia, North Macedonia, Poland, Serbia, Ukraine | À vérifier |
Essais cliniques
13| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Ublituximab | SEP | Phase 2 | NCT07503873 | A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS) | RECRUITING |
| Ublituximab | SEP | Phase 2/3 | NCT07220252 | Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis | RECRUITING |
| Venetoclax | SEP | Phase 1/2 | NCT03379051 | Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL | TERMINATED |
| ENABLE — A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS) | SEP | À vérifier | NCT06433752 | ENABLE — A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS) | RECRUITING |
| Ublituximab | SEP | Phase 3 | NCT05877963 | ENHANCE — Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab | RECRUITING |
| Ublituximab | SEP | Phase 3 | NCT04130997 | An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| PROVIDE — A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk | SEP | À vérifier | NCT06143514 | PROVIDE — A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk | RECRUITING |
| Ublituximab | SEP | Phase 3 | NCT07211633 | A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS) | ACTIVE_NOT_RECRUITING |
| Ublituximab | SEP | Non applicable | NCT06864936 | Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis | RECRUITING |
| Ublituximab | Myasthénie | Phase 2 | NCT07673744 | A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG) | RECRUITING |
| Azercabtagene zapreleucel (azer-cel) | Myasthénie | Phase 1 | NCT06680037 | A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders | RECRUITING |
| Ublituximab | Myopathies | Phase 2 | NCT07103746 | SUMMIT — Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy | RECRUITING |
| Ublituximab | SEP | Phase 4 | NCT07389590 | Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis | RECRUITING |
Publications
2| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Ublituximab | Optimizing Infusion Center Efficiency in Multiple Sclerosis: A Nursing Multicenter Survey on Organizational Impact of Ublituximab. | Healthcare (Basel, Switzerland) | ||
| Ublituximab | Infusion-related reactions and premedication patterns in ublituximab-treated multiple sclerosis patients: a multicenter real-world study. | Frontiers in neurology |